General information.
Tetrahydrofuran (THF), dichloromethane, and acetonitrile were purchased at ACS-grade from Fisher Scientific and dried via a solvent dispensing system prior to use in reactions. Other chemical reagents and ACS-grade solvents were purchased from Sigma Aldrich or Fisher Scientific and used without further purification. Unless otherwise stated, all reactions were performed under an atmosphere of N 2 . All reactions and chromatography fractions were monitored by thin layer chromatography (TLC) on silica-gel-coated glass plates with a F254 fluorescent indicator. Visualization was achieved by UV absorption by fluorescence quenching or permanganate stain (1.5 g KMnO 4 , 10 g K 2 CO 3 , 1.25 mL 10% NaOH in 200 mL of H 2 O). Flash chromatography was performed using Silicycle SiliaFlash P60, 230-400 mesh silica gel. NMR spectra were recorded on a Varian Unity 400 or Unity Inova 500 spectrometer. Electrospray ionization time-of-flight mass spectrometry (ESI-TOF MS) was performed on a Waters Quattro II quadrupole spectrometer.
Scheme S1. Synthesis of ABM2
Reagents and conditions: a) KOH, EtOH, 0 o C, 70%; b) 1) H 2 , Pd/C, THF; 2) NaBH 4 , NaOH, H 2 O, THF, 96% (two steps); c) DIPEA, CH 2 Cl 2 , 78%; d) 4,4-diphenylcyclohexanol, 1H-tetrazole, t BuOOH, MeCN; e) 1) NH 3 , MeOH; 2) LiOH, H 2 O, THF, 50% (three steps).
Synthesis of 4,4-diphenyl-2-cyclohexen-1-one.
Diphenylacetaldehyde (3.58 mL, 20.0 mmol) and 3-buten-2-one (2.46 mL, 30.0 mmol) were dissolved in anhydrous ethanol (15 mL) and chilled to 0 o C in an ice bath. Potassium hydroxide pellets (0.56 g, 10.0 mmol) were dissolved in anhydrous ethanol (10 mL) in a separate flask and chilled to 0 o C. The cold KOH solution was added slowly to the aldehyde solution over 10 min, and the reaction was stirred at 0 o C for 3 h, over which time a precipitate formed. The reaction was concentrated under reduced pressure, and the resulting residue was partitioned between H 2 O and Et 2 O. The mixture was acidified to pH 3 with 2 M aqueous HCl, and the layers were separated. The organic fraction was dried over Na 2 SO 4 , filtered and concentrated under reduced pressure. The crude material was purified by flash chromatography (SiO 2 , 9:1 hexanes/EtOAc) to yield the product (3.47 g, 14.0 mmol, 70%) as a white solid. R f 0.52 (4:1 hexane/EtOAc). Spectral data matched those reported previously. [1] 1.3 Synthesis of 4,4-diphenylcyclohexanol. To a solution of 4,4-diphenyl-2-cyclohexen-1-one (3.40 g, 13.7 mmol) in THF (30 mL) was added 10% palladium on carbon (140 mg). The reaction vessel was flushed with hydrogen gas, and the system was sealed under a hydrogen atmosphere (1 atm) and stirred vigorously for 20 h. The catalyst was removed by filtration through Celite, washing with SI-2 THF (15 mL), and the filtrate was chilled to 0 o C in an ice bath. Sodium borohydride (0.26 g, 6.85 mmol) was dissolved in 0.1 M aqueous NaOH (7 mL) in a separate flask and chilled to 0 o C, then added dropwise to the organic solution. The system was warmed to room temperature and stirred for 2 h. The reaction was then chilled to 0 o C, quenched with 2 M aqueous HCl (12 mL) and diluted with cold H 2 O (100 mL). The system was stirred at 0 o C for 30 min, over which time a white precipitate formed. The precipitate was isolated by filtration, washed with cold H 2 O and dried under reduced pressure to yield the product (3.32 g, 13.2 mmol, 96% over two steps) as a white solid. R f 0.26 (4:1 hexanes/EtOAc). Spectral data matched those reported previously. [2] 1.4 Synthesis of ethyl 6-[(2-cyanoethyl)(N,N-diisopropylamino)phosphino]oxyhexanoate. Ethyl 6-hydroxyhexanoate (2.44 mL, 15.0 mmol) and diisopropylethylamine (10.4 mL, 60.0 mmol) were dissolved in CH 2 Cl 2 (60 mL). 2-Cyanoethyl-N,N-diisopropylchlorophosphoramidite (3.51 mL, 15.8 mmol) was added dropwise, and the reaction was stirred for 2 h. The reaction was washed with icecold saturated aqueous NaHCO 3 , dried over Na 2 SO 4 , filtered and concentrated under reduced pressure. The crude material was purified by flash chromatography (SiO 2 , 9:1 hexane/EtOAc with 0.1% Et 3 N) to yield the product (4.20 g, 11.7 mmol, 78%) as a colorless liquid. R f 0.80 (2:1 hexane/EtOAc). Spectral data matched those reported previously. [3] 1.5 Synthesis of ABM2. Synthesis was performed with modification from a previous report.
[ 8 .45 mmol) was added, and the reaction was stirred under N 2 for 3 h. A 70% w/w aqueous solution of tert-butylhydroperoxide (8 mL) was added, and the reaction stirred for an additional 1 h, then concentrated under reduced pressure. The resulting residue was taken up in EtOAc, washed with 10% Na 2 S 2 O 3 , saturated aqueous NaHCO 3 and brine, dried over Na 2 SO 4 , filtered and concentrated under reduced pressure. The crude material was purified by flash chromatography (SiO 2 , 1:1 hexanes/EtOAc with 0.1% Et 3 N) to yield a colorless oil (R f 0.13, 1:1 hexanes/EtOAc). This oil was taken up in 2 M ammonia in methanol (80 mL) and stirred under N 2 for 12 h to remove the cyanoethyl substituent. The reaction was concentrated, and the resulting oil was taken up in THF (10 mL) and chilled to 0 o C in an ice bath. A 2 M aqueous solution of lithium hydroxide (5 mL) was added, and the reaction was warmed to room temperature and stirred for 2 h to hydrolyze the ethyl ester. The reaction was concentrated and taken up in water (100 mL). The solution was acidified to pH 2 with 2 M aqueous HCl, forming a white precipitate that was extracted with EtOAc (3 x 50 mL). The organic fractions were combined, dried over Na 2 SO 4 , filtered and concentrated to yield the product (1.94 g, 4.35 mmol, 54% over three steps) as an off-white solid after lyophilization from 1:1 benzene/acetonitrile. R f 0.45 (4:1:1 BuOH/H 2 O/AcOH). Enamine (Monmouth Jct., NJ; EN300-09570; 3-(naphthalene-2-sulfonamido)propanoic acid). ABM2 was synthesized according to established protocols as described above. [2, 4] 2.2 Procedures. Synthesis of compstatin analogs was performed using solid-phase peptide synthesis as previously described. [5, 6] Rink amide MBHA resin was used for the synthesis of all peptides, unless otherwise specified. After deprotection of the Fmoc group (5% piperazine in NMP with 0.1 M Oxyma), the resin was washed with NMP and DCM, and then individual amino acids were coupled to the resin. For each coupling, 3 equivalents of the amino acid, Oxyma, and DIC were used, with 10 min preactivation in NMP. All couplings were performed for 1 h and monitored by either Kaiser test or chloranil test. In case of a positive test result, the coupling was repeated until a negative test result was observed. i) In the cases of the conjugation of albumin-binding molecules, the appropriate acid was coupled to the amino terminus of the peptide on resin (ABM1: DIPEA, HATU, DMF; ABM2: DIPEA, PyBOP, NMP, DCM). [4, 7] ii) In the cases of the biotin-labeled peptides, Fmoc-Lys(biotin)-OH was used as the first amino acid to be coupled on the resin, followed by miniPEG and compstatin sequence. Upon completion of the solid phase synthesis, the peptides were cleaved from the resin with a mixture of 90% TFA, 5% thioanisole, 3% EDT and 2% anisole for 2 h. The peptides were precipitated and washed three times with ice-cold diethyl ether. The liquid was separated by centrifugation and decanted. The crude peptides were dissolved in acetonitrile:water (1:1) and filtered through a Puradisc syringe filter (0.45 µm PVDF, Whatman). The pH of the solution was adjusted to 7-8 using 5% aqueaous ammonium hydroxide. Dilute hydrogen peroxide (1:100, 2 eq.) was added to the solution under vigorous stirring. Once the reaction was completed (as detected my MALDI mass spectrometry), TFA was added to lower the pH to 2, and the solution was lyophilized. The crude peptide was then purified by reverse phase HPLC (XBridge Prep C18, 5 µm, 30×150 mm column) and eluted with a gradient of acetonitrile in aqueous 0.1% TFA solution at a flow rate of 10 mL/min. The purified peptides were >95% pure as determined by analytical HPLC (XBridge C18, 5 µm, 4.6×150 mm column). The mass of each peptide was confirmed using MALDI micro MX instrument (Waters, Milford, MA) or a SYNAPT G2-S high-resolution mass spectrometer (Waters).
SPR analysis

Interaction of Compstatin analogues with C3b
The binding affinity and kinetic profiles of the compstatin analogs with C3b was characterized by surface plasmon resonance (SPR) using a Biacore 3000 instrument (GE Healthcare, Piscataway, NJ) using previously established assay conditions. [6] Data were recorded at 25 ºC using PBS-T (10 mM sodium phosphate, 150 mM NaCl, 0.005% Tween-20, pH 7.4) as running buffer. Biotinylated C3b was captured on flow cells of a streptavidin sensor chip (GE Healthcare) at densities of about 3000 and 5000 resonance units (RU); untreated flow cells were used as a reference surface. A single cycle approach was used for kinetic analysis; sets of five increasing concentrations of each compound (2.5-40 nM) were injected over the chip surface consecutively in a single cycle without regeneration at a flow rate of 30 µL/min. Individual injections within a cycle were 2 min long with a 5-min dissociation between injections. After the end of the last injection, a 40-min dissociation time was allowed. The corresponding untagged compstatin analog (C20 or Cp40) was included in each experimental series as an internal control. Data were processed in Scrubber (v2.0c; Bio-Logic Software, Campbell, Australia); the signals from an untreated flow cell and an ensemble of buffer blank injections were subtracted to correct for buffer effects and injection artifacts. The kinetic evaluation was performed in BiaEvaluation using a single cycle kinetic template (kindly provided by GE Healthcare) by globally fitting each data set to a 1:1 Langmuir binding model to achieve association and dissociation rates (k a and k d , respectively); the equilibrium dissociation constant (K D ) was calculated from the equation Figure S1 ). Each assay was performed at least twice.
SI-4
Interaction of ABM-Compstatin conjugates with albumin
ABM2-Cp20-miniPEG-Lys(biotin) and Cp40-miniPEG-Lys(biotin) were synthesized via SPPS as described above. Streptavidin was immobilized on all flow cells of CM5 sensor chips (GE Healthcare) using standard amine coupling under 30 ºC. Biotinylated ABM2-Cp20 and Cp40 were captured on individual flow cells at densities of about 100 resonance units (RU); untreated flow cells were used as a reference surface. Sets of five increasing concentrations (6.3-100 µM) of albumin from different species (human, mouse, bovine, rabbit and baboon) were injected over the chip surface (Figure S2 ). Data were recorded at 25 ºC using PBS-T (10 mM sodium phosphate, 150 mM NaCl, 0.005% Tween-20, pH 7.4) as running buffer. Data were processed in Scrubber (v2.0c; Bio-Logic Software, Campbell, Australia); the signals from an untreated flow cell and buffer blank injections were subtracted. Apparent binding affinities (K D app ) were calculated by fitting the steady state responses to a singlebinding-site model.
Competition analysis of ABM2-Cp20
Human serum albumin (50 µM), (S)-ibuprofen (50, 100, 250, 500 µM), and mixtures of HSA and ibuprofen were individually injected to the ABM2-Cp20-miniPEG-Lys(biotin) immobilized sensor chip (as described above). Data were recorded at 25 ºC using PBS-T (10 mM sodium phosphate, 150 mM NaCl, 0.005% Tween-20, pH 7.4) as running buffer, and untreated flow cells were used as a reference surface. (S)-ibuprofen shows the dose-dependent blockade of HSA binding to the sensor chip ( Figure  S3 ).
Inhibition of complement activation
The potency of the compstatin analogs to inhibit complement activation initiated via the classical pathway was assessed by an established ELISA. [8] Each peptide was dissolved in water, and its concentration was determined by Nanodrop using the absorbance at 280 nm. Inhibition of immune complex-mediated complement activation by each peptide was determined over a concentration range of 0.01µM and ~10 µM as described before. [8] The percent inhibition was plotted against the peptide concentration, and the resulting data set was fitted to the logistic dose-response function to obtain IC 50 values (Figure S4 ).
Plasma Protein Binding (Equilibrium Dialysis)
Reagents and Materials
A rapid equilibrium dialysis (RED) device with inserts (MWCO 8 K) was used (Thermo Scientific). C3-depleted serum (product no. A314) was purchased from Complement Technology, Tyler, TX. Purified C3 (Complement Technology, A113c) was added to C3-depleted serum at a defined, physiologically relevant concentration (5 µM) to maintain the sample matrix and inhibitor-target ratio in comparative experiments (referred to as C3-positive serum).
Procedure for equilibrium dialysis
Equilibrium dialysis using RED device was performed to determine the plasma protein binding. The inserts were soaked in water for 10 min before discarding the water (twice), and then used immediately. [9] A mixture of 90 µL C3-depleted or C3-positive serum and 10 µL compstatin sample (5 or 10 µM) in PBS buffer (10% DMSO, 0.5% Tween 20, 0.2% sodium azide) was placed in the plasma chamber, and 300 µL PBS buffer (1% DMSO and 0.05% Tween 20) was placed in the buffer chamber. The final DMSO concentration of the dialysis system was 1%. The plate was covered with a sealing tape and incubated at 37 ºC on an orbital shaker (200 rpm) for 24 h. Each sample was analyzed at least twice.
SI-5
Procedure for sample analysis
A 50-µL aliquot of each post-dialysis sample from both the plasma and buffer chambers was pipetted into separate LoBind tubes (Eppendorf). The samples from plasma chambers were diluted with 50 µL PBS, while samples from buffer chambers were diluted with C3-depleted, or C3 positive serum (matrix match). All samples were diluted to 100 µL using 4% H 3 PO 4 to dissociate the peptides. The mixture was then subjected to solid phase extraction (Oasis ® HLB 96-well Plate, 10 mg Sorbent per Well, 30 µm Particle Size) and eluted with 200 µL 65% ACN/0.1% formic acid (Cp20) or eluted with 200 µL 85% ACN/0.1% formic acid (ABM2-Cp20). The eluent was injected into the UPLC-HDMS system consisting of an online ACQUITY UPLC (Waters BEH C18 column, 130Å, 1.7 µm, 2.1 mm × 150 mm) coupled to a SYNAPT G2-S HDMS instrument equipped with an ESI source (capillary voltage was set to 3.2 kV, the cone voltage to 30 V and the source temperature to 120 ºC). MS peak areas of the peptide were determined by integration for the quantification. [6] The unbound fraction of the peptide in plasma (%free) was calculated from the ratio of the buffer side response to the plasma side response. The bound fraction of the compound was calculated as follows: %bound = 100 -%free.
Binding model of ABM2-Cp20
Moloc (Gerber Molecular Design, http://www.moloc.ch) was used for the docking study that evaluated the binding of ABM2-Cp20 to the compstatin binding site based on the available co-crystal structure of C3c with compstatin analog 4W9A (PDB code: 2QKI). [10] The initial structural model of the ABM2-Cp20 was manually built based on the C3c-bound structure of 4W9A and docked into the compstatin binding pocket of human C3c. The modeling image was rendered using PyMol (http://www.pymol.org). Figure S1 . Kinetic analysis of peptides as listed in Table 1 
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